Search research articles
Contact Us
Filters
Showing results (361-370 of 391) with videos related to
Page
of 40
Sort By:
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]
|
November 5, 2020
[Exploratory research on developing lung cancer risk prediction model in female non-smokers]
Z Y Lyu, N Li, S H Chen, et al.
Oncogene
|
March 21, 2000
The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma
S Ren, M J Smith, I D Louro, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology
|
April 28, 2020
Accuracy of prenatal ultrasound screening to identify fetuses infected by cytomegalovirus which will develop severe long-term sequelae
M Leruez-Ville, S Ren, J-F Magny, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi
|
July 31, 2018
[Alcohol consumption and the risk of lung cancer in males: a prospective cohort study]
L P Wei, N Li, G Wang, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]
|
May 11, 2018
[Tea consumption and the risk of lung cancer in Chinese males: a prospective cohort study]
X Li, N Li, G Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 5, 2015
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
C Zhou, Y L Wu, G Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2013
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
G Chen, J Feng, C Zhou, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]
|
March 19, 2020
[Priority setting in scaled-up cancer screening in China: an systematic review of economic evaluation evidences]
J F Shi, A Y Mao, Y N Bai, et al.
Zhonghua Yi Xue Za Zhi
|
October 31, 2017
[Relationship between inflammatory markers and the risk of colorectal cancer in Kailuan male cohort]
G Wang, W G Xu, F Li, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi
|
June 5, 2018
[Association between total cholesterol and risk of lung cancer incidence in men: a prospective cohort study]
Z Y Lyu, N Li, G Wang, et al.
Page
of 40
Search research articles
Search
Showing results (361-370 of 391) with videos related to
Sort By:
Page
of 40
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]
|
November 5, 2020
[Exploratory research on developing lung cancer risk prediction model in female non-smokers]
Z Y Lyu, N Li, S H Chen, et al.
Oncogene
|
March 21, 2000
The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanoma
S Ren, M J Smith, I D Louro, et al.
Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology
|
April 28, 2020
Accuracy of prenatal ultrasound screening to identify fetuses infected by cytomegalovirus which will develop severe long-term sequelae
M Leruez-Ville, S Ren, J-F Magny, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi
|
July 31, 2018
[Alcohol consumption and the risk of lung cancer in males: a prospective cohort study]
L P Wei, N Li, G Wang, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]
|
May 11, 2018
[Tea consumption and the risk of lung cancer in Chinese males: a prospective cohort study]
X Li, N Li, G Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 5, 2015
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
C Zhou, Y L Wu, G Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2013
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
G Chen, J Feng, C Zhou, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]
|
March 19, 2020
[Priority setting in scaled-up cancer screening in China: an systematic review of economic evaluation evidences]
J F Shi, A Y Mao, Y N Bai, et al.
Zhonghua Yi Xue Za Zhi
|
October 31, 2017
[Relationship between inflammatory markers and the risk of colorectal cancer in Kailuan male cohort]
G Wang, W G Xu, F Li, et al.
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi
|
June 5, 2018
[Association between total cholesterol and risk of lung cancer incidence in men: a prospective cohort study]
Z Y Lyu, N Li, G Wang, et al.
Page
of 40